Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

alpha clash anti-IL-2 antibody fusion protein LAT010

An antibody fusion protein and interleukin-2 (IL-2) immunocytokine, with potential antineoplastic activity. Upon administration of the alpha-clash anti-IL-2 antibody fusion protein LAT010, the IL-2 moiety targets and binds to the intermediate-affinity IL-2 receptor beta,gamma (IL-2Rbg), thereby selectivity activating CD8+ T cells and natural killer (NK) cells against tumor cells. The alpha-clash anti-IL-2 antibody moiety of LAT010 prevents LAT010 from activating the high-affinity IL2Ralpha,beta,gamma receptor complex which may prevent severe IL-2-mediated systemic toxic effects.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:a-Clash IL-2 antibody fusion protein LAT010
antibody fusion protein LAT010
IL-2-based immunocytokine LAT010
immunocytokine LAT010
Code name:LAT 010
LAT-010
LAT010
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search